


### LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A compound based on the structure of kahalalide F according to formula 1:



wherein L-Orn at position 8 is substituted by another natural or non natural amino acid, and/or is masked with one or more substituent organic groups; and

wherein said compound may optionally differ from formula 1 by modification of the terminal acyl group; or a pharmaceutically acceptable salt thereof.

2-8. (Canceled)

9. (Previously presented) A compound according to claim 1, wherein the amino acid at position 8 is a masked L-Orn.

10. (Previously presented) A compound according to claim 1, wherein L-Orn at position 8 has been substituted by another natural or non-natural amino acid.

11. (Canceled)

12. (Previously presented) A compound according to claim 1, wherein the terminal acyl group is changed.

13. (Original) A compound according to claim 12, wherein the terminal acyl is 4(S)-methylhexyl.

14. (Canceled)

15. (Previously presented) A compound according to claim 1, based on the structure of kahalalide F of formula 1 designated KF, wherein said compound is selected from

[Glu<sup>8</sup>]-KF,

[Lys<sup>8</sup>]-KF,

[Lys<sup>8</sup>, (4S)-MeHex<sup>14</sup>]-KF,

[N(Me)<sub>2</sub>,N'(Me)<sub>2</sub>-Arg<sup>8</sup>]-KF,

[N(Me,Ph),N'(Me)<sub>2</sub>-Arg<sup>8</sup>]-KF,

[N(CH<sub>2</sub>)<sub>4</sub>,N'(Me)<sub>2</sub>-Arg<sup>8</sup>]-KF,

[N(CH<sub>2</sub>)<sub>4</sub>,N'(CH<sub>2</sub>)<sub>4</sub>-Arg<sup>8</sup>]-KF,

[Nδ(CHN(CH<sub>2</sub>)<sub>4</sub>-N'(CH<sub>2</sub>)<sub>4</sub>)-Orn<sup>8</sup>]-KF,

[Ne(Me)<sub>3</sub>-Lys<sup>8</sup>, (4S)-MeHex<sup>14</sup>]-KF,

[Orn(N<sup>8</sup>TFA)<sup>8</sup>, (4S)-MeHex<sup>14</sup>]-KF, and

[Orn(Biot)<sup>8</sup>]-KF;

wherein the amino acid or group indicated between brackets is the modification introduced in the structure of kahalalide F, or a pharmaceutically acceptable salt thereof.

16. (Previously presented) A compound according to claim 9, wherein L-Orn at position 8 is masked with one or more substituents selected from the group consisting of alkyl groups and heterocyclic groups.

17. (Previously presented) A compound according to claim 10, wherein the L-Orn at position 8 has been substituted by D-Orn, or a masked natural amino acid.

18. (Previously presented) A compound according to claim 17, wherein the masked natural amino acid is arginine or lysine with one or more alkyl, phenyl or oligomethylene substituents.

19. (Previously presented) A compound according to claim 10, wherein the L-Orn at position 8 has been substituted by Glu or Lys.

20. (Previously presented) A compound according to claim 1, wherein the L-Orn at position 8 has been replaced by [N(Me)<sub>2</sub>,N'(Me)<sub>2</sub>-Arg], [N(Me,Ph),N'(Me)<sub>2</sub>-Arg], [N(CH<sub>2</sub>)<sub>4</sub>,N'(Me)<sub>2</sub>-Arg], [N(CH<sub>2</sub>)<sub>4</sub>,N'(CH<sub>2</sub>)<sub>4</sub>-Arg], [N<sup>δ</sup>(CHN(CH<sub>2</sub>)<sub>4</sub>,N'(CH<sub>2</sub>)<sub>4</sub>)-Orn], [N<sup>ε</sup>(Me)<sub>3</sub>-Lys], [Orn(N<sup>δ</sup>Tfa)], or [Orn(Biot)] and, optionally, 5-MeHex at position 14 has been replaced by (4S)-MeHex.

21. (Previously presented) A compound according to claim 1, wherein the terminal acyl group has been replaced by Icos, (c/t)-4-Me-cHexa, Und, (4R)-MeHex, (4RS)-MeHex, (4S)-MeHex, Oct, p-MeBza, Bza, p-CF<sub>3</sub>Bza, 3,5-dFPhAc, Pipe, p-CF<sub>3</sub>Cinn, p-CF<sub>3</sub>PhAc, Pfh, 6-OHep, 6,6-dFHep, or 4-GuBut; and the L-Orn at position 8 has been replaced by L-Lys.

22. (Previously presented) A compound according to claim 1, wherein the terminal acyl group has been replaced by AM, AO, or C(=N(CH<sub>3</sub>)<sub>2</sub>) and the L-Orn at position 8 has been replaced by L-Lys.

23. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, vehicle or diluent.

24. (Withdrawn) A method of treating a mammal affected by cancer which comprises administering to the affected individual a therapeutically effective amount of a compound according to claim 1.

25. (Withdrawn) The method of claim 24 wherein the mammal is a human.